急性心肌梗死患者血清胎盘生长因子的动态变化及意义
|
摘要
目的:胎盘生长因子( placental growth factor, PLGF/PlGF)是血管内皮生长因子(vascular endothelial growth factor,VEGF)家族中的一员。研究显示它可以刺激血管平滑肌细胞生长,促进巨嗜细胞的趋化性聚集,并诱导其产生组织因子如肿瘤坏死因子和单核细胞趋化性蛋白-1,促发炎症反应,可作为动脉粥样硬化不稳定炎症斑块的一个主要助长因素。同时,C-反应蛋白作为一种炎症因子亦是动脉粥样硬化不稳定炎症斑块的一个助长因素。因此,对胎盘生长因子及超敏C-反应蛋白的进一步研究将有助于提高对动脉粥样硬化发生发展的认识,为动脉粥样硬化的防治提供一个新的思路。本实验主要研究急性心肌梗死(acute myocardial infarction,AMI)患者血清胎盘生长因子水平及超敏C-反应蛋白(high-sensitivity C-reactive protein,Hs-CRP)的动态变化及其与心肌梗死面积大小、心室重构程度的关系。
方法:AMI组患者60例,男33例,女27例,年龄37-82岁,平均(56.4±8.0)岁。并将所收AMI患者分为溶栓再通组与非溶栓组,其中溶栓再通组男性29例,女性6例,平均年龄(52.8±7.2)岁,非溶栓组男性18例,女性7例,平均年龄(51.8±9.1)岁。正常健康人30例,其中男性12例,女性18例,年龄为31-62岁,平均(52.1±6.6)岁。所有的研究对象除外体重指数(BMI)≥25kg/m2和<18.5kg/m2患者,除外脑血管病、全身大动脉疾病、肝肾疾病及代谢性疾病(糖尿病、甲状腺功能亢进)及炎症患者。各组研究对象在年龄、性别、BMI方面,差异无统计学意义。所有AMI研究对象于起病第12小时、第3天、第7天时采集肘静脉血5ml,对照组采集空腹肘静脉血5ml,胎盘生长因子采用酶联免疫吸附测定法(ELISA)测定;Hs-CRP采用免疫透射比浊法测定;并测定AMI 14天时超声心动图,了解左心室射血分数(left ventricular ejection, LVEF),左心室舒张末期容积(left ventricular end-diastolic volume, LVEDV),观察PlGF与LVEF及LVEDV的相关性;观察AMI组与对照组血清PlGF、Hs-CRP指标的变化;溶栓再通组与非溶栓组各指标间的变化;各指标之间的相关性;以及各指标与血清心肌酶谱相关性,及其对心室重构的影响。
结果:AMI患者发病12小时、第3天、第7天血清PlGF分别为(17.47±4.85)pg/mL、(20.47±5.42)pg/mL、(9.30±2.89)pg/mL,除第7天组外均明显高于健康对照组(7.56±1.37)pg/mL(P<0.01);其中第3天显著高于第7天,第7天与对照组相比差异无统计学意义;而同时测定的Hs-CRP分别为(33.57±32.18)mg/L、(41.76±10.19)mg/L、(28.03±8.34 )mg/L亦明显高于健康对照组(1.5±2.0)mg/L(P<0.01)。血清PlGF与血清CK-MB峰值呈正相关(r=0.131;P>0.05);Hs-CRP与血清CK-MB峰值呈正相关(r=0.364;P<0.01);同一时间点的PlGF与Hs-CRP呈正相关(r=0.014;P>0.05)。血清PlGF与LVEF呈显著负相关(r=-0.654;P<0.01),与LVEDV呈显著正相关(r=0.845;P<0.01)。
结论:1 AMI患者第12小时、第3天、第7天血清PlGF、Hs-CRP水平显著高于健康人群,其中第3天最高,提示PlGF和Hs-CRP可能参与AMI的病理发展过程;2溶栓再通组PlGF与Hs-CRP显著低于非溶栓组,提示PlGF和Hs-CRP的水平受再灌注影响;3血清PlGF与Hs-CRP呈正相关,PlGF与心肌梗死标志物CK-MB呈正相关,Hs-CRP与CK-MB呈正相关,提示PlGF和心肌损伤面积有关。4血清PlGF与LVEF呈显著负相关,与LVEDV呈显著正相关,提示PlGF水平可能影响左心室重构。
Objective: Placental growth factor ( PlGF ) is a member of the vascular endothelial growth factor (VEGF)family of growth factors. PlGF stimulates vascular smooth muscle cell growth, recruits macrophages into atherosclerotic lesions, up-regulates production of tumor necrosis factor and monocyte chemotactic protein -1 by macrophages, stimulates the inflammtory reaction. It plays a fundamental role for unstable inflammation plaque of atherosclerosis.Simultaneously,CRP also plays a fundamental role for unstable inflammation plaque of atherosclerosis as a inflammation factor. Thus, furture research of PlGF and Hs-CRP will elevate the recogniaion of early and advanced atherosclerotic lesions. Furthermore, we will investigate the role of PlGF on the development of acute myocardial infarction (AMI).
Methods: 60 patients with acute myocardial infarction (AMI), who came from the inpatients of 2th hospital affiliated with the HEBEI Medical University ( 33 males and 27 females ), with average age of (56.4±8.0) years. The patients with AMI were divided into two groups : the thrombolysis group ( 29 males and 6 females ) with average age of (52.8±7.2) years and the non-thrombolysis group ( 18 males and 7 females ) with average age of (51.8±9.1) years. 30 healthy staffs were recruited as normal control group. All subjects not only had excluded body mass index ( BMI )≥25kg/m2 and <18.5kg/m2, but also had no other diseases such as Cerebrovascular disease, Main Artery disease, Liver and Kidney disease, Metabolic disease ( Diabetes, Hyperthyreosis ). The age, sex , BMI showed no difference among three groups. Taking ulnar venous blood 5ml on an empty stomach, infusing anticoagulation tube, using centrifugal machine, 3000 r /min, centrifuging 10min, the plasma in Eppendorf was preserved in -80℃refrigerator. Serum placental growth factor (PlGF) were detected by enzyme-linked immuneosorbent assay (ELISA), while the levels of Hs-CRP were detected by immunity transmission turbidity. Cardiac ultrasonography were detected on 14 days of onset, the relationship between adiponectin and the markers of Serum placental growth factor, Hs-CRP was analyzed.
Results: The level of Serum placental growth factor at 12hours and the 3days and 7 days were respectively (17.47±4.85) pg/mL, (20.47±5.42) pg/mL, (9.30±2.89) pg/mL, significantly raised than control group (7.56±1.37) pg/mL (P<0.01) except the 7 days group, the level of Serum Hs-CRP at the same time were respectively (33.57±32.18) mg/L, (41.76±10.19) mg/L, (28.03±8.34)mg/L, significantly raised than control group (1.5±2.0) mg/L(P<0.05). The level of placental growth factor was positively correlated with that of CK-MB (r=0.131;P>0.05) and Hs-CRP was positively correlated with that of CK-MB (r=0.364;P<0.01), while placental growth factor was positively with Hs-CRP ( r=0.014;P>0.05). The level of placental growth factor was negatively correlated with left ventricular ejection (LVEF) (r=-0.654;P<0.01), and positive correlation with left ventricular end-diastolic volume(LVEDV) (r= 0.845; P<0.01).
Conclusion: 1 The level of serum PlGF and Hs-CRP at 12hours and the 3days and 7 days were significantly raised than control group,and the 3 days were the highest,suggested that PlGF and Hs-CRP contribute to the pathophysiological process of aute myocardial infarction; 2 The level of serum PlGF and Hs-CRP of the thrombolysis group were significantly raised than that of the nonthrombolysis group,suggested that the level of serum PlGF and Hs-CRP were affected by reperfusion ; 3 The level of serum PlGF was positively correlated with that of CK-MB ,and the level of Hs-CRP was positively correlated with that of CK-MB while PlGF was positively with Hs-CRP , suggested that PlGF related to myocardial injury area; 4 The level of PlGF was negatively correlated with LVEF, and positive correlation with LVEDV,suggested that PlGF may influence left ventricular remodeling.
方法:AMI组患者60例,男33例,女27例,年龄37-82岁,平均(56.4±8.0)岁。并将所收AMI患者分为溶栓再通组与非溶栓组,其中溶栓再通组男性29例,女性6例,平均年龄(52.8±7.2)岁,非溶栓组男性18例,女性7例,平均年龄(51.8±9.1)岁。正常健康人30例,其中男性12例,女性18例,年龄为31-62岁,平均(52.1±6.6)岁。所有的研究对象除外体重指数(BMI)≥25kg/m2和<18.5kg/m2患者,除外脑血管病、全身大动脉疾病、肝肾疾病及代谢性疾病(糖尿病、甲状腺功能亢进)及炎症患者。各组研究对象在年龄、性别、BMI方面,差异无统计学意义。所有AMI研究对象于起病第12小时、第3天、第7天时采集肘静脉血5ml,对照组采集空腹肘静脉血5ml,胎盘生长因子采用酶联免疫吸附测定法(ELISA)测定;Hs-CRP采用免疫透射比浊法测定;并测定AMI 14天时超声心动图,了解左心室射血分数(left ventricular ejection, LVEF),左心室舒张末期容积(left ventricular end-diastolic volume, LVEDV),观察PlGF与LVEF及LVEDV的相关性;观察AMI组与对照组血清PlGF、Hs-CRP指标的变化;溶栓再通组与非溶栓组各指标间的变化;各指标之间的相关性;以及各指标与血清心肌酶谱相关性,及其对心室重构的影响。
结果:AMI患者发病12小时、第3天、第7天血清PlGF分别为(17.47±4.85)pg/mL、(20.47±5.42)pg/mL、(9.30±2.89)pg/mL,除第7天组外均明显高于健康对照组(7.56±1.37)pg/mL(P<0.01);其中第3天显著高于第7天,第7天与对照组相比差异无统计学意义;而同时测定的Hs-CRP分别为(33.57±32.18)mg/L、(41.76±10.19)mg/L、(28.03±8.34 )mg/L亦明显高于健康对照组(1.5±2.0)mg/L(P<0.01)。血清PlGF与血清CK-MB峰值呈正相关(r=0.131;P>0.05);Hs-CRP与血清CK-MB峰值呈正相关(r=0.364;P<0.01);同一时间点的PlGF与Hs-CRP呈正相关(r=0.014;P>0.05)。血清PlGF与LVEF呈显著负相关(r=-0.654;P<0.01),与LVEDV呈显著正相关(r=0.845;P<0.01)。
结论:1 AMI患者第12小时、第3天、第7天血清PlGF、Hs-CRP水平显著高于健康人群,其中第3天最高,提示PlGF和Hs-CRP可能参与AMI的病理发展过程;2溶栓再通组PlGF与Hs-CRP显著低于非溶栓组,提示PlGF和Hs-CRP的水平受再灌注影响;3血清PlGF与Hs-CRP呈正相关,PlGF与心肌梗死标志物CK-MB呈正相关,Hs-CRP与CK-MB呈正相关,提示PlGF和心肌损伤面积有关。4血清PlGF与LVEF呈显著负相关,与LVEDV呈显著正相关,提示PlGF水平可能影响左心室重构。
Objective: Placental growth factor ( PlGF ) is a member of the vascular endothelial growth factor (VEGF)family of growth factors. PlGF stimulates vascular smooth muscle cell growth, recruits macrophages into atherosclerotic lesions, up-regulates production of tumor necrosis factor and monocyte chemotactic protein -1 by macrophages, stimulates the inflammtory reaction. It plays a fundamental role for unstable inflammation plaque of atherosclerosis.Simultaneously,CRP also plays a fundamental role for unstable inflammation plaque of atherosclerosis as a inflammation factor. Thus, furture research of PlGF and Hs-CRP will elevate the recogniaion of early and advanced atherosclerotic lesions. Furthermore, we will investigate the role of PlGF on the development of acute myocardial infarction (AMI).
Methods: 60 patients with acute myocardial infarction (AMI), who came from the inpatients of 2th hospital affiliated with the HEBEI Medical University ( 33 males and 27 females ), with average age of (56.4±8.0) years. The patients with AMI were divided into two groups : the thrombolysis group ( 29 males and 6 females ) with average age of (52.8±7.2) years and the non-thrombolysis group ( 18 males and 7 females ) with average age of (51.8±9.1) years. 30 healthy staffs were recruited as normal control group. All subjects not only had excluded body mass index ( BMI )≥25kg/m2 and <18.5kg/m2, but also had no other diseases such as Cerebrovascular disease, Main Artery disease, Liver and Kidney disease, Metabolic disease ( Diabetes, Hyperthyreosis ). The age, sex , BMI showed no difference among three groups. Taking ulnar venous blood 5ml on an empty stomach, infusing anticoagulation tube, using centrifugal machine, 3000 r /min, centrifuging 10min, the plasma in Eppendorf was preserved in -80℃refrigerator. Serum placental growth factor (PlGF) were detected by enzyme-linked immuneosorbent assay (ELISA), while the levels of Hs-CRP were detected by immunity transmission turbidity. Cardiac ultrasonography were detected on 14 days of onset, the relationship between adiponectin and the markers of Serum placental growth factor, Hs-CRP was analyzed.
Results: The level of Serum placental growth factor at 12hours and the 3days and 7 days were respectively (17.47±4.85) pg/mL, (20.47±5.42) pg/mL, (9.30±2.89) pg/mL, significantly raised than control group (7.56±1.37) pg/mL (P<0.01) except the 7 days group, the level of Serum Hs-CRP at the same time were respectively (33.57±32.18) mg/L, (41.76±10.19) mg/L, (28.03±8.34)mg/L, significantly raised than control group (1.5±2.0) mg/L(P<0.05). The level of placental growth factor was positively correlated with that of CK-MB (r=0.131;P>0.05) and Hs-CRP was positively correlated with that of CK-MB (r=0.364;P<0.01), while placental growth factor was positively with Hs-CRP ( r=0.014;P>0.05). The level of placental growth factor was negatively correlated with left ventricular ejection (LVEF) (r=-0.654;P<0.01), and positive correlation with left ventricular end-diastolic volume(LVEDV) (r= 0.845; P<0.01).
Conclusion: 1 The level of serum PlGF and Hs-CRP at 12hours and the 3days and 7 days were significantly raised than control group,and the 3 days were the highest,suggested that PlGF and Hs-CRP contribute to the pathophysiological process of aute myocardial infarction; 2 The level of serum PlGF and Hs-CRP of the thrombolysis group were significantly raised than that of the nonthrombolysis group,suggested that the level of serum PlGF and Hs-CRP were affected by reperfusion ; 3 The level of serum PlGF was positively correlated with that of CK-MB ,and the level of Hs-CRP was positively correlated with that of CK-MB while PlGF was positively with Hs-CRP , suggested that PlGF related to myocardial injury area; 4 The level of PlGF was negatively correlated with LVEF, and positive correlation with LVEDV,suggested that PlGF may influence left ventricular remodeling.
引文
1 Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA ,2004, 291(4): 435-441
2 程文立. 炎性血清标记物与动脉硬化斑块稳定性的研究近况.心血管病学进展.2005,26(3):262-264
3 Li J, Brown LF, Hibberd MG, et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol, 1996, 270: 1803-1811
4 沈红玲, 陈汉平. 胎盘生长因子及其受体的分子特性的研究进展.国外医学妇幼保健分册, 2004,15(5):298-300
5 刘斌. 胎盘生长因子(PlGF)的生物学功能. 国外医学·生理、病理科学与临床分册, 2003,23(4):407-409
6 Luttun A, Tjwa M, Moons L, et al. Revascularization of ischem ictissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by Anti-flt1. Nature Med,2002,8(8):831-840
7 Iwawa H, Uemura S, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.The American College of Cardiology. 2006, 47(8): 1559-1567
8 Selvaraj SK,Giri RK, Perelman N,et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003,102(4): 1515-1524
9 Khurana R, Moons L, Shafi S, et al. Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation. Circulation. 2005, 111 (21): 2828-2836
10 杨文齐, 毛淑丹, 陶贵周. 急性心肌梗死后左室重构的研究现状. 中国误诊学杂志, 2005,5(10):1821-1823
11 Deten A, Volz HC, Briest W, et al. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Expression ental studies in rates. Cardiovasc Res, 2002,55:329-340
12 黄维周, 时昭红等. C-反应蛋白临床研究进展.中国实用内科杂志,1996,16(4):245-246
13 Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol, 2003,41(4):S37-S42
14 Hashimoto H, Kitagawa K, Hougaku H, et al. C-reative protein is an independent predictor of the rate of increase in early carotid atherosclerosis.Circulation,2001,104(1):63-67
15 Liuzoo G, Basucci LM, Gallimore JR, et al. Elevated levels of c-reactive protein at discharge in predict recurrent instablity. Circulation, 1999,99:855-860
16 Koenig w, Lowel H, Baumert J, et al. C-reative protein modulates risk prediction and tropon in patients with unstable angina of non-Qwave myocardial infarction. Cardiovasc Res, 1999,42:240-245
17 Frerranti SD, Rifai N. C-reative protein and cardivascular disease : review rish prediction and inferrention. Clin Chim Acta,2002,317:1-15
18 Biasucci LM, Liuzzo G, Colizzi C,et al. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J. 2001, 2(3): 164-171
19 Heeschen C, Hamm CW, Bruemmer J,et al. Predictive value of Creactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol. 2000, 35(6):1535 -1542
20 Pepys MB, Hirschfield GM . C-reactive protein and its role in the pathogenesis of myocardial infarction. Ital Heart J. 2001,2(11):804-806
21 马永娜, 李拥军, 姜红岩. 白细胞介素-6 及 c-反应蛋白与急性心肌梗死后心室重构的相关性研究.中国循环杂志, 2005, 20(6) :454-456
22 Rifai N, Ridker PM. High-sensitivity C-reactive protein : a novel and promising of coronary heart disease. Clin Chem, 2001,47(3):403-411
1 Ji WR, Qi P , et al. Placenta growth factor:identification and characterization of a nove lisoform generated by RNA alternative splicing.Biochem Biophys Res Commun, 1997, 235(3): 493-498
2 Green CJ, Lichtlen P, Huynh NT,et al. Placenta Growth Factor Gene Expression Is Induced by Hypoxia in Fibroblasts: A Central Role for Metal Transcription Factor-1. Cancer Research,2001,61(3):2696-2703
3 Mohammed KA, Nasreen N, Tepper RS,et al. Cyclic stretch induces PlGF expression in bronchial airway epithelial cells via nitric oxide release. Am J Physiol Lung Cell Mol Physiol, 2007 ,292(2):L559-566
4 lyerS, Leonidas D D, Swam inathan G J, et al. The crystal structure of human placental growth factor-1(PGF-1),an angiogenic protein,at 2.0 A resolution.J Biol Chem, 2001, 276: 12153-12161
5 Yang W, Ahn H, Hinrichs M, et al. Evidence of a novel isoform of placental growth factor(PGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol, 2003,60(1): 53-60
6 Ahmed A, Dunk C, Ahmad S, et al. Regulation of placental vascular endothelial growth factor(VEGF)and placental growth factor(PGF)and soluble Flt-1 by oxygen.Placenta, 2000,21:S16-S24
7 Khaliq A, Dunk C, Jiang J, et al. Hypoxia down-regulates placenta growth factor,whereas fetal growth restriction upregulates placenta growth factor expression:Molecular evidence for”placental hyperoxia”in intrauterine growth restriction. Lab Invest, 1999, 79:151-170
8 Park JE, Chen H , Winer J , et al. Placenta growth factorPotentiation of vascular endothelial growth factor bioactivity, in vitro and in vi-vo, and high affinity binding to Flt-1but not to Flk-1/KDR.J Biol Chem, 1994, 269(41): 25646-25654
9 Fong GH, Rossant J, Gertsentein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothe lium. Nature, 1995, 376(6535):66-70
10 Ratajczak MZ, Ratajczak J, Machalinski B, et al. Role of vascular endothelial growth factor(VEGF) and placenta- derived growth factor (PLGF) in regulating human haem opoietic cell growth. Br J Haematol, 1998 103(4): 969-979
11 Autiero M, Luttun A, Tjwa M, et al . Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: noveltargets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost, 2003, 1(7): 1356-370
12 Rohit Khurana , MD, Lieve Moons, PhD, Shahida Shafi , PhD, et al. Plancental growth factor promotes atherosclerotic intinmal thickening and macrophage accumulation. Circulation, 2005,111,2828-2836
13 Luttun A, Tjwa M, Moons L, et al. Revascularization of ischem ictissues by PLGF treatment , and inbibition of tum or angiogenesis, arthritis and atherosclerosis by anti-Flt-1. Nat Med , 2002,8(8):831-840
14 Odorisio T, Schietroma C, Zaccaria ML, et al. Mice overexpressing meability. J Cell Sci, 2002, 115(Pt12): 2559-2567
15 Bottomley MJ, Webb NJ, Watson CJ,et al. Placenta growth factor (PlGF) induces vascular endothelia lgrowth factor (VEGF) secretion from mononuclear cells and is co- expressed with VEGF in synovial fluid. Clin Exp Immunol, 2000, 119(1):182-188
16 Rohit Khu rana , MD, Lieve Moons, PhD, Shahida Shafi, PhD, et al. Placental growth factor promotes atherosclerotic intimal thickning and macrophage accumulation. Circulation, 2005, 111: 2828-2836
17 Oura H, Bertoncini J, Velasco P, et al . A critical role of placental growth factor in the induction of onflammation and edem a formation. Blood, 2003,101(2):560-567
18 Kodama J, Seki N, Tokumo K, et al. Placenta growth factor is abundantly expressed in human cervical squamous cell carcinoma. Eur J Gynaecol Oncol ,1997,18(6):508-510
19 Donnini S, Machein MR , Plate KH, et al. Expression and localization of placenta growth factor and PLGF receptors in human meningiomas. J Pathol, 1999,189(1):66-71
20 Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endithelial cells and macrophages.Cancer Res,2002,62(10):2749-2752
21 Nomura M, Yanagishi S, Harada S, et al. Placenta growth factor (PlGF) mRNA expression in brain tumors. J Neurooncol, 1998,40(2):123-130
22 Hattori K , Heissig B, Wu Y, et al. Placental growth factorreconstitutes hematopoiesis by recruiting VEGFR-1(+) stem cells from bone -marrow microenvironment. Nat Med , 2002, 8(8):841-849
23 Khurana R, Moons L, Shafi S, et al. Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation. Circulation, 2005, 111(21): 2828-2836
24 Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol, 2003,41(4):S37-S42
25 Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA ,2004, 291(4): 435-441
26 Koenig W,Khuseyinova N.Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007,27(1):15-26
27 Iwawa H, Uemura S, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.The American College of Cardiology. 2006, 47(8): 1559-1567
28 Heeschen C, Dimmeler S ,Fichtlscherer S, et al. Prognostic value of placental growth actue chest pain. Rev Cardiovasc Med ,2005 winter 6(1):59-60
2 程文立. 炎性血清标记物与动脉硬化斑块稳定性的研究近况.心血管病学进展.2005,26(3):262-264
3 Li J, Brown LF, Hibberd MG, et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol, 1996, 270: 1803-1811
4 沈红玲, 陈汉平. 胎盘生长因子及其受体的分子特性的研究进展.国外医学妇幼保健分册, 2004,15(5):298-300
5 刘斌. 胎盘生长因子(PlGF)的生物学功能. 国外医学·生理、病理科学与临床分册, 2003,23(4):407-409
6 Luttun A, Tjwa M, Moons L, et al. Revascularization of ischem ictissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by Anti-flt1. Nature Med,2002,8(8):831-840
7 Iwawa H, Uemura S, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.The American College of Cardiology. 2006, 47(8): 1559-1567
8 Selvaraj SK,Giri RK, Perelman N,et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003,102(4): 1515-1524
9 Khurana R, Moons L, Shafi S, et al. Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation. Circulation. 2005, 111 (21): 2828-2836
10 杨文齐, 毛淑丹, 陶贵周. 急性心肌梗死后左室重构的研究现状. 中国误诊学杂志, 2005,5(10):1821-1823
11 Deten A, Volz HC, Briest W, et al. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Expression ental studies in rates. Cardiovasc Res, 2002,55:329-340
12 黄维周, 时昭红等. C-反应蛋白临床研究进展.中国实用内科杂志,1996,16(4):245-246
13 Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol, 2003,41(4):S37-S42
14 Hashimoto H, Kitagawa K, Hougaku H, et al. C-reative protein is an independent predictor of the rate of increase in early carotid atherosclerosis.Circulation,2001,104(1):63-67
15 Liuzoo G, Basucci LM, Gallimore JR, et al. Elevated levels of c-reactive protein at discharge in predict recurrent instablity. Circulation, 1999,99:855-860
16 Koenig w, Lowel H, Baumert J, et al. C-reative protein modulates risk prediction and tropon in patients with unstable angina of non-Qwave myocardial infarction. Cardiovasc Res, 1999,42:240-245
17 Frerranti SD, Rifai N. C-reative protein and cardivascular disease : review rish prediction and inferrention. Clin Chim Acta,2002,317:1-15
18 Biasucci LM, Liuzzo G, Colizzi C,et al. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J. 2001, 2(3): 164-171
19 Heeschen C, Hamm CW, Bruemmer J,et al. Predictive value of Creactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol. 2000, 35(6):1535 -1542
20 Pepys MB, Hirschfield GM . C-reactive protein and its role in the pathogenesis of myocardial infarction. Ital Heart J. 2001,2(11):804-806
21 马永娜, 李拥军, 姜红岩. 白细胞介素-6 及 c-反应蛋白与急性心肌梗死后心室重构的相关性研究.中国循环杂志, 2005, 20(6) :454-456
22 Rifai N, Ridker PM. High-sensitivity C-reactive protein : a novel and promising of coronary heart disease. Clin Chem, 2001,47(3):403-411
1 Ji WR, Qi P , et al. Placenta growth factor:identification and characterization of a nove lisoform generated by RNA alternative splicing.Biochem Biophys Res Commun, 1997, 235(3): 493-498
2 Green CJ, Lichtlen P, Huynh NT,et al. Placenta Growth Factor Gene Expression Is Induced by Hypoxia in Fibroblasts: A Central Role for Metal Transcription Factor-1. Cancer Research,2001,61(3):2696-2703
3 Mohammed KA, Nasreen N, Tepper RS,et al. Cyclic stretch induces PlGF expression in bronchial airway epithelial cells via nitric oxide release. Am J Physiol Lung Cell Mol Physiol, 2007 ,292(2):L559-566
4 lyerS, Leonidas D D, Swam inathan G J, et al. The crystal structure of human placental growth factor-1(PGF-1),an angiogenic protein,at 2.0 A resolution.J Biol Chem, 2001, 276: 12153-12161
5 Yang W, Ahn H, Hinrichs M, et al. Evidence of a novel isoform of placental growth factor(PGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol, 2003,60(1): 53-60
6 Ahmed A, Dunk C, Ahmad S, et al. Regulation of placental vascular endothelial growth factor(VEGF)and placental growth factor(PGF)and soluble Flt-1 by oxygen.Placenta, 2000,21:S16-S24
7 Khaliq A, Dunk C, Jiang J, et al. Hypoxia down-regulates placenta growth factor,whereas fetal growth restriction upregulates placenta growth factor expression:Molecular evidence for”placental hyperoxia”in intrauterine growth restriction. Lab Invest, 1999, 79:151-170
8 Park JE, Chen H , Winer J , et al. Placenta growth factorPotentiation of vascular endothelial growth factor bioactivity, in vitro and in vi-vo, and high affinity binding to Flt-1but not to Flk-1/KDR.J Biol Chem, 1994, 269(41): 25646-25654
9 Fong GH, Rossant J, Gertsentein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothe lium. Nature, 1995, 376(6535):66-70
10 Ratajczak MZ, Ratajczak J, Machalinski B, et al. Role of vascular endothelial growth factor(VEGF) and placenta- derived growth factor (PLGF) in regulating human haem opoietic cell growth. Br J Haematol, 1998 103(4): 969-979
11 Autiero M, Luttun A, Tjwa M, et al . Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: noveltargets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost, 2003, 1(7): 1356-370
12 Rohit Khurana , MD, Lieve Moons, PhD, Shahida Shafi , PhD, et al. Plancental growth factor promotes atherosclerotic intinmal thickening and macrophage accumulation. Circulation, 2005,111,2828-2836
13 Luttun A, Tjwa M, Moons L, et al. Revascularization of ischem ictissues by PLGF treatment , and inbibition of tum or angiogenesis, arthritis and atherosclerosis by anti-Flt-1. Nat Med , 2002,8(8):831-840
14 Odorisio T, Schietroma C, Zaccaria ML, et al. Mice overexpressing meability. J Cell Sci, 2002, 115(Pt12): 2559-2567
15 Bottomley MJ, Webb NJ, Watson CJ,et al. Placenta growth factor (PlGF) induces vascular endothelia lgrowth factor (VEGF) secretion from mononuclear cells and is co- expressed with VEGF in synovial fluid. Clin Exp Immunol, 2000, 119(1):182-188
16 Rohit Khu rana , MD, Lieve Moons, PhD, Shahida Shafi, PhD, et al. Placental growth factor promotes atherosclerotic intimal thickning and macrophage accumulation. Circulation, 2005, 111: 2828-2836
17 Oura H, Bertoncini J, Velasco P, et al . A critical role of placental growth factor in the induction of onflammation and edem a formation. Blood, 2003,101(2):560-567
18 Kodama J, Seki N, Tokumo K, et al. Placenta growth factor is abundantly expressed in human cervical squamous cell carcinoma. Eur J Gynaecol Oncol ,1997,18(6):508-510
19 Donnini S, Machein MR , Plate KH, et al. Expression and localization of placenta growth factor and PLGF receptors in human meningiomas. J Pathol, 1999,189(1):66-71
20 Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endithelial cells and macrophages.Cancer Res,2002,62(10):2749-2752
21 Nomura M, Yanagishi S, Harada S, et al. Placenta growth factor (PlGF) mRNA expression in brain tumors. J Neurooncol, 1998,40(2):123-130
22 Hattori K , Heissig B, Wu Y, et al. Placental growth factorreconstitutes hematopoiesis by recruiting VEGFR-1(+) stem cells from bone -marrow microenvironment. Nat Med , 2002, 8(8):841-849
23 Khurana R, Moons L, Shafi S, et al. Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation. Circulation, 2005, 111(21): 2828-2836
24 Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol, 2003,41(4):S37-S42
25 Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA ,2004, 291(4): 435-441
26 Koenig W,Khuseyinova N.Biomarkers of Atherosclerotic Plaque Instability and Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007,27(1):15-26
27 Iwawa H, Uemura S, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.The American College of Cardiology. 2006, 47(8): 1559-1567
28 Heeschen C, Dimmeler S ,Fichtlscherer S, et al. Prognostic value of placental growth actue chest pain. Rev Cardiovasc Med ,2005 winter 6(1):59-60